AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17947500 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA)
Number of subjects: 7
Study 17947500 — intervention group
Group type: COMPARATOR
Intervention: n-6 polyunsaturated fatty acids (PUFA)
Number of subjects: 7
Study 16476915 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training program
Number of subjects: 765
Study 16476915 — intervention group
Group type: COMPARATOR
Intervention: Standard conditioning exercises (Control)
Number of subjects: 765
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 1.0 mg of Cu/2000 kcal and 99 mg of Mg/2000 kcal for 81 days
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 1.0 mg of Cu/2000 kcal and 399 mg of Mg/2000 kcal for 81 days
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 3.0 mg of Cu/2000 kcal and 99 mg of Mg/2000 kcal for 81 days
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 3.0 mg of Cu/2000 kcal and 399 mg of Mg/2000 kcal for 81 days
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary copper
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium deprivation
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary magnesium and low dietary copper
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium deprivation with luxuriant copper
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium deprivation with low dietary copper
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary magnesium before depletion
Number of subjects: 19
Study 12831948 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of Mg/d
Number of subjects: 19
Study 11111106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid perfusion
Number of subjects: 12
Study 11111106 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 12
Study 9155573 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (8 mg/hour after a bolus of 80 mg)
Number of subjects: 40
Study 9155573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (0.25 mg/kg/hour after a bolus of 50 mg)
Number of subjects: 40
Study 7970431 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase (flow and static) scrotal scintigraphy
Number of subjects: 43
Study 3297481 — intervention group
Group type: EXPERIMENTAL
Intervention: Kathon CG 15 ppm active ingredient in a leave-on body lotion
Number of subjects: 209
Study 3297481 — intervention group
Group type: COMPARATOR
Intervention: Control lotion without Kathon CG
Number of subjects: 209
Study 31263013 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid artificial tears (Lacribell; Latinofarma)
Number of subjects: 140
Study 31263013 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears gel (Vidisic Gel; Bausch and Lomb)
Number of subjects: 140
Study 27740878 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 (selective glucocorticoid receptor modulator)
Number of subjects: 0
Study 27740878 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated airway tissue exposure
Number of subjects: 0
Study 27740878 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in systemic exposure (plasma concentration profile, AUC, Cmax)
Number of subjects: 0
Study 24877682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel syndrome (CTS)
Number of subjects: 22
Study 24877682 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 22
Study 24877682 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback provided for the first 30 seconds
Number of subjects: 22
Study 23964934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily)
Number of subjects: 1110
Study 23964934 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily for 4 weeks, followed by 2 weeks without treatment)
Number of subjects: 1110
Study 23964934 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1110
Study 23964934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1110
Study 22024490 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE 8 g/d
Number of subjects: 100
Study 22024490 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE 14 g/d
Number of subjects: 100
Study 22024490 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE 18 g/d
Number of subjects: 100
Study 22024490 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE 24 g/d
Number of subjects: 100
Study 22024490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18804132 — intervention group
Group type: EXPERIMENTAL
Intervention: IC51 vaccine in TBE ELISA-positive subjects
Number of subjects: 420
Study 18804132 — intervention group
Group type: COMPARATOR
Intervention: IC51 vaccine in TBE ELISA-negative subjects
Number of subjects: 420
Study 17227526 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging
Number of subjects: 27
Study 17227526 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging in active UC segments
Number of subjects: 27
Study 17227526 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT imaging in normal sites above affected segments
Number of subjects: 27
Study 15040548 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Parkinson's disease
Number of subjects: 42
Study 15040548 — intervention group
Group type: COMPARATOR
Intervention: Nondemented individuals without Parkinson's disease
Number of subjects: 42
Study 14509504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (3 ml applied to the dissected mediastinum)
Number of subjects: 43
Study 14509504 — intervention group
Group type: COMPARATOR
Intervention: No fibrin glue applied
Number of subjects: 43
Study 10232311 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim 160 mg, sulphamethoxazole 800 mg) daily
Number of subjects: 545
Study 10232311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study 10232311 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 545
Study 8726365 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsing words 3 times
Number of subjects: 72
Study 8726365 — intervention group
Group type: COMPARATOR
Intervention: Rehearsing words 1 time
Number of subjects: 72
Study 8726365 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of information processing measures (rehearsal time, articulation speed, DSST scores)
Number of subjects: 72
Study 8726365 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-independent speed of processing (DSST scores, articulation speed)
Number of subjects: 72
Study 8726365 — intervention group
Group type: EXPERIMENTAL
Intervention: DSST scores
Number of subjects: 72
Study 1988077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg GM-CSF
Number of subjects: 15
Study 1988077 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg GM-CSF
Number of subjects: 15
Study 1988077 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg GM-CSF
Number of subjects: 15
Study 1988077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6880226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g per day for 8 weeks followed by surgery if symptomatic recurrence occurs
Number of subjects: 100
Study 6880226 — intervention group
Group type: COMPARATOR
Intervention: Repeated courses of cimetidine 1 g per day for 8 weeks in case of recurrence
Number of subjects: 100
Study 6880226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (either single course or repeated)
Number of subjects: 100
Study 6880226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment (single vs repeated courses)
Number of subjects: 100
Study 2876664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg/day
Number of subjects: 20
Study 2876664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 40 mg/day
Number of subjects: 20
Study 2876664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 40 mg/day and 80 mg/day
Number of subjects: 20
Study 30054049 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent cetuximab (Arm-A)
Number of subjects: 193
Study 30054049 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX-6 + cetuximab (Arm-B)
Number of subjects: 193
Study 28662222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 652
Study 28662222 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 652
Study 28662222 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint high risk
Number of subjects: 652
Study 28662222 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint low risk
Number of subjects: 652
Study 26353832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalve cast
Number of subjects: 46
Study 26353832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure‐relieving ankle‐foot orthosis
Number of subjects: 46
Study 26353832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 23830138 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged Modules 1 and 2 (hip abductors and knee extensors during early stance, plantarflexors during late stance)
Number of subjects: 0
Study 23830138 — intervention group
Group type: EXPERIMENTAL
Intervention: Merged Modules 1 and 4 (hamstrings during late swing into early stance)
Number of subjects: 0
Study 23830138 — intervention group
Group type: EXPERIMENTAL
Intervention: General rehabilitation focus on plantarflexors
Number of subjects: 0
Study 21196894 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement plus bioactive glass (Perioglas)
Number of subjects: 8
Study 21196894 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement alone
Number of subjects: 8
Study 18504550 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (DAA)
Number of subjects: 7683
Study 18504550 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory trial with DAA
Number of subjects: 7683
Study 18504550 — intervention group
Group type: COMPARATOR
Intervention: Anti‐thrombin‐III
Number of subjects: 7683
Study 18504550 — intervention group
Group type: COMPARATOR
Intervention: Tissue factor pathway inhibitor
Number of subjects: 7683
Study 17061004 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Norms Marketing (SNM) campaigns
Number of subjects: 2771
Study 17061004 — intervention group
Group type: COMPARATOR
Intervention: Control group institutions
Number of subjects: 2771
Study 12738312 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet assay
Number of subjects: 65
Study 12738312 — intervention group
Group type: COMPARATOR
Intervention: Eppendorf PO2 histograph
Number of subjects: 65
Study 10770187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg) for 5 yr (group I)
Number of subjects: 447
Study 10770187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III)
Number of subjects: 447
Study 10770187 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 yr followed by alendronate (5 mg) for 2 yr (group II)
Number of subjects: 447
Study 9313386 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management program
Number of subjects: 44
Study 8393108 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (Do) 200 mg on the first day and 100 mg for 4 days, followed by Amoxicillin/Clavulanate potassium (Au) 500 mg 3 times daily for 5 days
Number of subjects: 11
Study 8393108 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (Do) for 10 days
Number of subjects: 11
Study 3552892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 28
Study 3552892 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 28
Study 30121688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone-impregnated Gelfoam dressing
Number of subjects: 8
Study 30121688 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-impregnated Gelfoam dressing
Number of subjects: 8
Study 27048836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplementation of pasteurised Bacteroides xylanisolvens DSM 23964 for 8 weeks
Number of subjects: 140
Study 27048836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 24502652 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term professional oral health care (once per week for 1 month)
Number of subjects: 30
Study 23564179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU nasal spray
Number of subjects: 16
Study 23564179 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 16
Study 20101370 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-facilitated PCI
Number of subjects: 170
Study 20101370 — intervention group
Group type: COMPARATOR
Intervention: TNK alone
Number of subjects: 170
Study 18847422 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible bicarbonate solution
Number of subjects: 0
Study 18847422 — intervention group
Group type: COMPARATOR
Intervention: Biocompatible lactate solution
Number of subjects: 0
Study 18847422 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate/lactate solutions
Number of subjects: 0
Study 18847422 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible solutions
Number of subjects: 0
Study 18847422 — intervention group
Group type: EXPERIMENTAL
Intervention: New solutions
Number of subjects: 0
Study 18847422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis solutions with higher glucose degradation products
Number of subjects: 0
Study 16635293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment group (100 mg orally every day)
Number of subjects: 164
Study 16635293 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional supporting treatment)
Number of subjects: 164
Study 16635293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 16635293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment group
Number of subjects: 164
Study 14616259 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g)
Number of subjects: 698
Study 14616259 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 698
Study 10980913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (875 mg capsules containing 850 to 882 mg EPA and DHA)
Number of subjects: 11324
Study 10980913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 11324
Study 10980913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil
Number of subjects: 11324
Study 10980913 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 11324
Study 9337948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention
Number of subjects: 18
Study 9337948 — intervention group
Group type: COMPARATOR
Intervention: Anxiety management
Number of subjects: 18
Study 8473719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 36
Study 8473719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 36
Study 8473719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3928960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide with forced diuresis (Group A)
Number of subjects: 11
Study 3928960 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide without forced diuresis (Group B)
Number of subjects: 11
Study 31237044 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG+ DLBCL
Number of subjects: 118
Study 31237044 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulation of miR-4638-5p
Number of subjects: 118
Study 31237044 — intervention group
Group type: COMPARATOR
Intervention: ERG- DLBCL
Number of subjects: 118
Study 28712475 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 111
Study 28712475 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 111
Study 25287626 — intervention group
Group type: EXPERIMENTAL
Intervention: e-SAID intervention (completed the e-SAID questionnaire)
Number of subjects: 168
Study 25287626 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed the same anxiety questions with a time-lapse)
Number of subjects: 168
Study 23064290 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1(7‐37)amide (0.4 pmol min⁻¹ kg⁻¹)
Number of subjects: 14
Study 23064290 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study 22134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual violence
Number of subjects: 4351
Study 22134450 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed violence
Number of subjects: 4351
Study 19592388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer (BP) stent
Number of subjects: 605
Study 19592388 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer (PP; Cypher) stent
Number of subjects: 605
Study 19592388 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free (PF) stent
Number of subjects: 605
Study 16875919 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Lifestyle Management Intervention (ELMI)
Number of subjects: 302
Study 16875919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study 12631004 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading scale of radiographic findings in the pubic bone and symphysis in athletes
Number of subjects: 20
Study 12631004 — intervention group
Group type: COMPARATOR
Intervention: Control group 1: 20 healthy age‐matched men
Number of subjects: 20
Study 12631004 — intervention group
Group type: COMPARATOR
Intervention: Control group 2: 120 adults (66 men and 54 women) in 9 age groups between 15 and 90 years of age
Number of subjects: 20
Study 11194264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring relationships
Number of subjects: 959
Study 11194264 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 959
Study 9177376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg (n = 36, 29 completed)
Number of subjects: 91
Study 9177376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n = 35, 28 completed)
Number of subjects: 91
Study 9177376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20, 13 completed)
Number of subjects: 91
Study 8257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin taken 5 min after antacid (Maalox 30 ml)
Number of subjects: 12
Study 8257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin taken 4 h before antacid (Maalox 30 ml)
Number of subjects: 12
Study 8257146 — intervention group
Group type: COMPARATOR
Intervention: Rufloxacin alone
Number of subjects: 12
Study 4041513 — intervention group
Group type: EXPERIMENTAL
Intervention: nonsedating doses of diazepam
Number of subjects: 20
Study 4041513 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30253049 — intervention group
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid/Clobetasol Propionate Compound Ointment
Number of subjects: 240
Study 30253049 — intervention group
Group type: COMPARATOR
Intervention: calcipotriol/betamethasone dipropionate ointment
Number of subjects: 240
Study 26559681 — intervention group
Group type: EXPERIMENTAL
Intervention: B9 (10mg/day orally) for 2 months, followed by B12 (1000 μg) for 2 months, then B9 + B12 for 2 months (Group A)
Number of subjects: 132
Study 26559681 — intervention group
Group type: EXPERIMENTAL
Intervention: B12 for 2 months, followed by B9 for 2 months, then B9 + B12 for 2 months (Group B)
Number of subjects: 132
Study 26559681 — intervention group
Group type: EXPERIMENTAL
Intervention: Wash-out period (t4) for both groups
Number of subjects: 132
Study 24655701 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional circulatory occlusion (RCO) during recovery after exercise
Number of subjects: 11
Study 24655701 — intervention group
Group type: COMPARATOR
Intervention: Normal recovery after exercise
Number of subjects: 11
Study 24655701 — intervention group
Group type: EXPERIMENTAL
Intervention: RCO
Number of subjects: 11
Study 22982080 — intervention group
Group type: EXPERIMENTAL
Intervention: Buried in Treasures (BIT) Workshop
Number of subjects: 0
Study 22982080 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 21088807 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 replacement
Number of subjects: 23
Study 21088807 — intervention group
Group type: COMPARATOR
Intervention: Simple observation (control)
Number of subjects: 23
Study 17389557 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir (TMC114) coadministered with low-dose ritonavir under fasted conditions
Number of subjects: 0
Study 17389557 — intervention group
Group type: COMPARATOR
Intervention: darunavir (TMC114) coadministered with low-dose ritonavir after a standard meal
Number of subjects: 0
Study 16372585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPFX) 200 mg/day for 21 days
Number of subjects: 26
Study 16372585 — intervention group
Group type: COMPARATOR
Intervention: Control treatment for 21 days
Number of subjects: 26
Study 11953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 500 microg thrice daily
Number of subjects: 42
Study 11953688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9708456 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided stent implantation (Group B)
Number of subjects: 155
Study 9708456 — intervention group
Group type: COMPARATOR
Intervention: Standard stent implantation without IVUS guidance (Group A)
Number of subjects: 155
Study 9621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet laser therapy (UVLT)
Number of subjects: 16
Study 9621317 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet irradiation (UVI)
Number of subjects: 16